RenovoRx Highlights Record Revenue and Clinical Progress at H.C. Wainwright Conference
Event summary
- RenovoRx CEO Shaun Bagai and CFO Mark Voll will present at the H.C. Wainwright conference on September 14, 2026.
- Record Q2 2026 revenue of $909,000 driven by increasing demand for RenovoCath.
- First clinical use of RenovoCath in sarcoma treatment at CARTI Cancer Center.
- Phase III TIGeR-PaC trial fully enrolled; completion expected in H1 2027.
- PK-PD data published in Cancer Chemotherapy and Pharmacology showed 51% local drug concentration.
The big picture
RenovoRx's presentation underscores its transition from clinical-stage to commercial-scale oncology player, with RenovoCath emerging as a key driver of revenue growth. The company's focus on targeted drug delivery aligns with broader industry trends toward precision oncology, while its Phase III trial progress positions it for potential regulatory milestones in 2027. The strategic anomaly here is the rapid commercial adoption of RenovoCath as a standalone device, which may accelerate its path to profitability ahead of clinical trial readouts.
What we're watching
- Commercial Expansion
- How RenovoRx will scale RenovoCath adoption beyond high-volume cancer centers.
- Clinical Validation
- Whether the TIGeR-PaC trial results will support broader oncology applications.
- Regulatory Pathway
- The pace at which RenovoRx advances its drug-device combination products through FDA approval.
Related topics